Codexis, Inc. (NASDAQ:CDXS) has earned a consensus recommendation of “Buy” from the eight research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $22.30.

Several equities analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Garrett Motion from a “sell” rating to a “hold” rating in a report on Friday, May 10th. ValuEngine raised shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. Finally, BidaskClub cut shares of Xilinx from a “buy” rating to a “hold” rating in a research note on Saturday, June 15th.

In other Codexis news, SVP James Lalonde sold 19,999 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $18.65, for a total transaction of $372,981.35. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.70% of the stock is owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in CDXS. Pratt Collard Advisory Partners LLC increased its stake in Codexis by 14.9% during the second quarter. Pratt Collard Advisory Partners LLC now owns 48,107 shares of the biotechnology company’s stock valued at $887,000 after purchasing an additional 6,250 shares during the last quarter. FMR LLC increased its stake in Codexis by 25.6% during the first quarter. FMR LLC now owns 917,537 shares of the biotechnology company’s stock valued at $18,837,000 after purchasing an additional 187,000 shares during the last quarter. Gilder Gagnon Howe & Co. LLC increased its stake in Codexis by 228.0% during the first quarter. Gilder Gagnon Howe & Co. LLC now owns 2,489,389 shares of the biotechnology company’s stock valued at $51,107,000 after purchasing an additional 1,730,434 shares during the last quarter. Advisory Services Network LLC bought a new stake in Codexis during the first quarter valued at $415,000. Finally, Marshall Wace North America L.P. bought a new stake in Codexis during the first quarter valued at $913,000. 85.18% of the stock is currently owned by institutional investors.

NASDAQ:CDXS traded down $0.31 during mid-day trading on Monday, hitting $18.53. 210,053 shares of the company’s stock traded hands, compared to its average volume of 395,812. The company has a current ratio of 3.42, a quick ratio of 3.38 and a debt-to-equity ratio of 0.51. The business has a 50 day simple moving average of $18.32. Codexis has a 1 year low of $12.85 and a 1 year high of $23.05. The stock has a market capitalization of $1.03 billion, a P/E ratio of -88.24 and a beta of -0.17.

Codexis (NASDAQ:CDXS) last posted its earnings results on Monday, May 6th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.09). Codexis had a negative net margin of 18.22% and a negative return on equity of 21.08%. The firm had revenue of $15.58 million during the quarter, compared to the consensus estimate of $14.83 million. Research analysts anticipate that Codexis will post -0.23 earnings per share for the current year.

About Codexis

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Recommended Story: Hedge Funds Explained

Analyst Recommendations for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.